Clinical Trial Update: IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating maintenance therapy with the IDH1 inhibitor ivosidenib after allogeneic stem cell transplantation in IDH1-mutant myeloid neoplasms has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: IDH1 Mutation Myeloid Neoplasms | Phase 1 | Status: COMPLETED